Multi-Kingdom Gut Microbiome Interaction Characteristics Predict Immune Checkpoint Inhibitor Efficacy Across Pan-Cancer Cohorts
Microorganisms · 14.11.2025 · 13 (11) · 2595
DOI: 10.3390/microorganisms13112595 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microorganisms, online erschienen am 14.11.2025. Verfasst von Tong Qiao und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine & Department of Food Science and Engineering, Jinan University, Guangzhou 510632, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangzhou Basic and Applied Basic Research Project, Guangdong Basic and Applied Basic Research Foundation.
Abstract (Originalsprache)
An increasing number of studies have confirmed that the gut microbiota, especially bacteria, is closely related to the efficacy of immune checkpoint inhibitor (ICI) therapy. However, the effectiveness of multi-kingdom microbiota and their interactions in predicting the therapeutic effect of ICI therapy remains uncertain. We integrated extensive gut metagenomic databases, including 1712 samples of 10 cohorts from 7 countries worldwide, to conduct rigorous differential analysis and co-occurrence network analysis targeting multi-kingdom microbiota (bacteria, fungi, archaea, and virus). We ultimately identified two subtypes (C1 and C2) by employing a weighted similarity network fusion (WSNF) method. Subtype C2 exhibited higher microbial diversity, better treatment response, and improved prognosis compared to subtype C1. Notably, subtype C2 was associated with higher abundance of beneficial genera such as Bacteroides and Kluyveromyces, while subtype C1 contained potentially detrimental taxa like Malassezia. A multi-kingdom model incorporating 32 genera demonstrated superior predictive accuracy for ICI therapy efficacy compared to single-kingdom models. Co-occurrence network analysis revealed a more robust and interconnected microbiome in subtype C2, suggesting a stable gut environment correlates with effective ICI therapy efficacy. This study highlights the potential of a multi-kingdom signature in predicting the efficacy of ICI therapy, offering a novel perspective for personalized therapy in oncology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Medicine & Department of Food Science and Engineering, Jinan University, Guangzhou 510632, China.
- State Key Laboratory of Food Science and Resources, Nanchang University, Nanchang 330027, China.
ORCID-Profile: Zhenjun Zhu
Förderung
- Guangzhou Basic and Applied Basic Research Project
- Guangdong Basic and Applied Basic Research Foundation
Zitieren
APA
Qiao, T., & Zhu, Z. (2025). Multi-Kingdom Gut Microbiome Interaction Characteristics Predict Immune Checkpoint Inhibitor Efficacy Across Pan-Cancer Cohorts. Microorganisms, 13(11), 2595. https://doi.org/10.3390/microorganisms13112595
Vancouver
Qiao T, Zhu Z. Multi-Kingdom Gut Microbiome Interaction Characteristics Predict Immune Checkpoint Inhibitor Efficacy Across Pan-Cancer Cohorts. Microorganisms. 2025;13(11):2595. doi:10.3390/microorganisms13112595
BibTeX
@article{Qiao2025,
author = {Qiao, Tong and Zhu, Zhenjun},
title = {Multi-Kingdom Gut Microbiome Interaction Characteristics Predict Immune Checkpoint Inhibitor Efficacy Across Pan-Cancer Cohorts},
journal = {Microorganisms},
year = {2025},
volume = {13},
number = {11},
pages = {2595},
doi = {10.3390/microorganisms13112595}
}
EUVIMED